Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase

被引:23
作者
Addlagatta, Anthony
Matthews, Brian W. [1 ]
机构
[1] Univ Oregon, Inst Mol Biol, Howard Hughes Med Inst, Eugene, OR 97403 USA
[2] Univ Oregon, Dept Phys, Eugene, OR 97403 USA
关键词
methionine aminopeptidase; fumagillin; cancer; angiogenesis;
D O I
10.1110/ps.062278006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Methionine aminopeptidases (MetAPs) remove the initiator methionine during protein biosynthesis. They exist in two isoforms, MetAP1 and MetAP2. The anti-angiogenic compound fumagillin binds tightly to the Type 2 MetAPs but only weakly to Type 1. High-affinity complexes of fumagillin and its relative ovalicin with Type 2 human MetAP have been reported. Here we describe the crystallographic structure of the low-affinity complex between ovalicin and Type 1 human MetAP at 1.1 angstrom resolution. This provides the first opportunity to compare the structures of ovalicin or fumagillin bound to a Type 1 and a Type 2 MetAP. For both Type 1 and Type 2 human MetAPs the inhibitor makes a covalent adduct with a corresponding histidine. At the same time there are significant differences in the alignment of the inhibitors within the respective active sites. It has been argued that the lower affinity of ovalicin and fumagillin for the Type 1 MetAPs is due to the smaller size of their active sites relative to the Type 2 enzymes. Comparison with the uncomplexed structure of human Type 1 MetAP indicates that there is some truth to this. Several active site residues have to move "outward'' by 0.5 angstrom or so to accommodate the inhibitor. Other residues move "inward.'' There are, however, other factors that come into play. In particular, the side chain of His310 rotates by 134 degrees into a different position where (together with Glu128 and Tyr195) it coordinates a metal ion not seen at this site in the native enzyme.
引用
收藏
页码:1842 / 1848
页数:7
相关论文
共 26 条
[1]   Structural basis for the functional differences between type I and type II human methionine aminopeptidases [J].
Addlagatta, A ;
Hu, XY ;
Liu, JO ;
Matthews, BW .
BIOCHEMISTRY, 2005, 44 (45) :14741-14749
[2]   Effects of angiogenesis inhibitors on multistage carcinogenesis in mice [J].
Bergers, G ;
Javaherian, K ;
Lo, KM ;
Folkman, J ;
Hanahan, D .
SCIENCE, 1999, 284 (5415) :808-812
[3]  
Bhargava P, 1999, CLIN CANCER RES, V5, P1989
[4]   A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases [J].
Brdlik, CM ;
Crews, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (10) :9475-9480
[5]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[6]   Structural evidence that the methionyl aminopeptidase from Escherichia coli is a mononuclear metalloprotease [J].
Cosper, NJ ;
D'souza, VM ;
Scott, RA ;
Holz, RC .
BIOCHEMISTRY, 2001, 40 (44) :13302-13309
[7]   Characterization of the active site and insight into the binding mode of the anti-angiogenesis agent fumagillin to the manganese(II)-loaded methionyl aminopeptidase from Escherichia coli [J].
D'souza, VM ;
Brown, RS ;
Bennett, B ;
Holz, RC .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2005, 10 (01) :41-50
[8]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[9]   Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin [J].
Griffith, EC ;
Su, Z ;
Turk, BE ;
Chen, SP ;
Chang, YH ;
Wu, ZC ;
Biemann, K ;
Liu, JO .
CHEMISTRY & BIOLOGY, 1997, 4 (06) :461-471
[10]   Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: Evidence for activity in non-small-cell lung cancer [J].
Herbst, RS ;
Madden, TL ;
Tran, HT ;
Blumenschein, GR ;
Meyers, CA ;
Seabrooke, LF ;
Khuri, FR ;
Puduvalli, VK ;
Allgood, V ;
Fritsche, HA ;
Hinton, L ;
Newman, RA ;
Crane, EA ;
Fossella, FV ;
Dordal, M ;
Goodin, T ;
Hong, WK .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) :4440-4447